Enzon Pharmaceuticals (ENZN) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'ENZON PHARMACEUTICALS INC	'
Entity Central Index Key	'0000727510	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'ENZN	'
Entity Common Stock, Shares Outstanding	'	44,068,299
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$21,691	$77,348
Marketable securities	0	119,391
Other current assets	642	1,904
Assets held for sale	529	0
Total current assets	22,862	198,643
Property and equipment	0	1,138
Total assets	22,862	199,781
LIABILITIES AND STOCKHOLDERS’ EQUITY	'	'
Accounts payable	201	776
Accrued expenses and other current liabilities	2,286	5,688
Notes payable	0	115,849
Total current liabilities	2,487	122,313
Accrued rent liability	596	0
Total liabilities	3,083	122,313
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock - $0.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at September 30, 2013 and December 31, 2012	0	0
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 44,068,299 shares at September 30, 2013 and 43,674,170 shares at December 31, 2012	441	437
Additional paid-in capital	154,515	224,796
Accumulated other comprehensive income	0	83
Accumulated deficit	-135,177	-147,848
Total stockholders' equity	19,779	77,468
Total liabilities and stockholders’ equity	$22,862	$199,781

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	44,068,299	43,674,170
Common stock, shares outstanding	44,068,299	43,674,170

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Royalties	$8,828	$10,919	$26,436	$31,011
Contract research and development	0	0	0	136
Miscellaneous revenue	0	202	631	806
Total revenues	8,828	11,121	27,067	31,953
Operating expenses:	'	'	'	'
Research and development - pipeline	653	3,954	2,525	16,541
Research and development - specialty and contracted services	0	10	0	123
General and administrative	2,259	3,209	7,606	11,242
Restructuring charges	794	-113	3,764	-220
Total operating expenses	3,706	7,060	13,895	27,686
Operating income	5,122	4,061	13,172	4,267
Other income (expense):	'	'	'	'
Investment income, net	4	1,386	534	2,387
Interest expense	0	-1,274	-2,124	-4,055
Other income (expense), net	195	2	1,061	-191
Total other income (expense)	199	114	-529	-1,859
Income before income tax expense	5,321	4,175	12,643	2,408
Income tax (benefit) expense	-241	0	-28	33
Net income	5,562	4,175	12,671	2,375
Earnings per common share	'	'	'	'
Basic (in dollars per share)	$0.13	$0.09	$0.29	$0.05
Diluted (in dollars per share)	$0.13	$0.08	$0.26	$0.05
Weighted-average shares - basic (in shares)	43,921	46,387	43,782	47,614
Weighted-average shares - diluted (in shares)	44,137	58,563	53,468	47,671
Special cash dividend paid per common share	$0	$0	$1.60	$0
Other comprehensive income (loss):	'	'	'	'
Net income	5,562	4,175	12,671	2,375
Available-for-sale marketable securities:	'	'	'	'
Unrealized holding gains arising during period	4	590	238	1,070
Reclassification adjustment for realized gains on sales included in net income	0	-979	-320	-960
Total other comprehensive income (loss)	4	-389	-82	110
Comprehensive income	$5,566	$3,786	$12,589	$2,485

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income	$12,671	$2,375
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation	218	3,500
Amortization and write-off of debt issuance costs	193	425
Stock-based compensation and employee purchase plan discount	-54	1,550
Gain on sales of marketable securities	-320	-960
Loss on early retirement of notes payable	0	212
Amortization of purchase premium on marketable securities	735	2,345
Gain on sale of assets	-1,060	-8
Changes in operating assets and liabilities	-2,276	-7,378
Net cash provided by operating activities	10,107	2,061
Cash flows from investing activities:	'	'
Purchases of property and equipment	0	-23
Proceeds from sale of assets	1,451	9
Proceeds from sales and maturities of marketable securities	118,894	265,314
Purchases of marketable securities	0	-195,413
Net cash provided by investing activities	120,345	69,887
Cash flows from financing activities:	'	'
Common stock dividend	-69,970	0
Repurchase of common stock	0	-21,439
Retirement of notes payable	-115,849	0
Repurchases of notes payable	0	-13,862
Proceeds from issuance of common stock	12	62
Withholding taxes - stock based compensation	-269	-102
Withdrawals/proceeds from employee stock purchase plan	-33	15
Net cash used in financing activities	-186,109	-35,326
Net (decrease) increase in cash and cash equivalents	-55,657	36,622
Cash and cash equivalents at beginning of period	77,348	104,324
Cash and cash equivalents at end of period	$21,691	$140,946

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	(1)   Description of Business
	Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of six marketed products, namely, PegIntron®, Sylatron®, Macugen®, CIMZIA®, Oncaspar and Adagen.  The Company currently has no clinical operations and limited corporate operations.  The Company operates in one business segment. The Company’s Principal Executive Officer (chief operating decision maker) reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. The Company’s operations and assets reside exclusively in the United States.
	The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs.  In December 2012, the Company announced that its Board of Directors retained Lazard Frères & Co. LLC to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets or a sale of the Company and that the Board of Directors established a special committee to oversee the sale review process. In connection with the sale review process, the Company substantially suspended all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders.  In April 2013, the Company announced that it had concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company.  The review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets.  In the same announcement, the Company also announced that its Board of Directors intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders.
	On April 30, 2013, pursuant to the terms of an asset purchase agreement entered into on the same date (the “Belrose APA”), the Company completed the sale of all of its right, title and interest in its Customized PEGylation Linker Technology platform and related assets to Belrose Pharma Inc. (“Belrose”) for aggregate consideration of $700,000.  The assets sold included (i) intellectual property and know-how associated with the PEGylation platform (including certain patents), (ii) patents and know-how related to PEG-SN38, (iii) patents and know-how associated with certain of the Company’s internal clinical programs and (iv) certain related supplies and equipment.  In addition, the Company assigned to Belrose the Company’s existing license agreement with Zhejiang Hisun Pharmaceutical Co., Ltd.  The Belrose APA had also provided for the sale by the Company of its interest in the Locked Nucleic Acid (LNA) Technology platform and related assets for $100,000 at a second closing; however, the conditions to the second closing were not satisfied.  The Belrose APA also entitles the Company to receive from Belrose additional potential payments, including a share of net revenues that may be received from Hisun related to PEG-SN38 rights in China as well as a share of other potential partnering revenues.  The achievement of any of these potential payments is uncertain.  The assets sold to Belrose did not include any of the Company’s existing rights to receive royalties on PegIntron®, Sylatron®, Macugen®, CIMZIA®, OMONTYS®, Oncaspar or Adagen.
	On October 21, 2013, the Company terminated its License and Collaboration Agreement with Santaris Pharma A/S (“Santaris”) whereby the Company will return to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin.  See Note 15, “Subsequent Event” for further details.
	The Company has no intention of resuming any clinical development activities.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Accounting [Text Block]	'
	(2)   Basis of Presentation
	Interim Financial Statements
	The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

New_Accounting_Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
New Accounting Pronouncements and Changes In Accounting Principles [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	(3)  New Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update “Comprehensive Income (Topic 220):  Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (ASU 2013-02).  ASU 2013-02 requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. GAAP to be reclassified in its entirety to net income.  The amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component.  An entity is required to provide this information together, in one location, either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements.  The amendments are effective prospectively for reporting periods beginning after December 15, 2012.  The adoption of ASU 2013-02 did not have a material impact on the Company’s financial position or results of operations.
	The FASB recently issued ASU “Presentation of Financial Statements (Topic 205) Liquidation Basis of Accounting” (ASU 2013-07) that requires an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent, as defined in ASU 2013-7. ASU 2013-7’s objective is to eliminate diverse practices by providing guidance about when and how to apply the model. The guidance applies to all entities except for investment companies regulated under the Investment Company Act of 1940.
	ASU 2013-7 is effective for both public and nonpublic entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. An entity preparing its financial statements on a going-concern basis at the effective date that is required to use the liquidation basis of accounting is required to account for any differences between its existing measurements and the measurements under ASU 2013-7 through a cumulative-effect adjustment. Early adoption is permitted. The Company has evaluated the impact of ASU 2013-7 on the Company’s consolidated financial statements, and has determined that it does not currently have an impact on Company’s financial statements.
	In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This update amends ASC 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The Company is currently evaluating the impact this update will have on its financial statements.

Financial_Instruments_and_Fair

Financial Instruments and Fair Value	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	(4)  Financial Instruments and Fair Value
	The carrying values of cash, cash equivalents, marketable securities, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s condensed consolidated balance sheets approximated their fair values at September 30, 2013 and December 31, 2012 due to their short-term nature.

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	(5)  Marketable Securities
	The Company held no marketable securities at September 30, 2013. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2012 were as follows (in thousands):
		Amortized		Gross		Gross		Fair
		Cost		Unrealized		Unrealized		Value*
				Holding Gains		Holding Losses
	Corporate bonds	$	86,769	$	82	$	-11	$	86,840
	Commercial paper		30,482		8		-		30,490
	U.S. government-sponsored agency		2,057		4		-		2,061
		$	119,308	$	94	$	-11	$	119,391
	*     Included in current marketable securities at December 31, 2012.
	All marketable securities at December 31, 2012 were classified as available-for-sale.
	For the three months ended September 30, 2013, the Company did not realize any gains from the sale of marketable securities.  For the nine months ended September 30, 2013, the Company realized gains from the sale of marketable securities of $0.3 million. For the three months ended September 30, 2012, the Company realized net gains from the sale of marketable securities of $1.0 million. For the nine months ended September 30, 2012, the Company realized net gains from the sale of marketable securities of $1.0 million. The Company includes realized gain and losses, if any, in the accompanying Condensed Consolidated Statements of Comprehensive Income, in Interest and Other Income.
	Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. As of December 31, 2012, marketable securities with fair value of $38.1 million were in an unrealized loss position. However, none of the underlying investments has been in a continuous loss position longer than twelve months, and no other-than-temporary impairment is deemed to have occurred.
	As of December 31, 2012, the Company’s marketable securities are all valued based on Level 2 inputs. Fair value is determined from available Level 2 vendor quoted prices utilizing observable inputs based on active markets. The Company utilizes a financial institution to provide pricing for securities in the Company’s portfolio, and reviews documentation from the sources that detailed the pricing techniques and methodologies used by these sources and determines if their policies adequately considered market activity, either based on specific transactions for the particular security type or based on modeling of securities with similar credit quality, duration, yield and structure that were recently transacted. The Company continues to monitor any changes or modifications to their process by reviewing their documentation on internal controls for pricing and market reviews.

Property_and_Equipment_and_Ass

Property and Equipment and Assets Held for Sale	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment and Assets Held for Sale [Text Block]	'
	(6)  Property and Equipment and Assets Held for Sale
	In connection with the sublease of a portion of its headquarters as discussed in Note 14, the Company plans to sell a portion of its property and equipment to Axcellerate and to sell its remaining property and equipment through a third party liquidator.  As such, the Company has classified its property and equipment as Assets Held for Sale as of September 30, 2013. The Company reduced the carrying value of its property and equipment to estimated fair market value based on third-party independent appraisals as of December 31, 2012.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	(7)  Notes Payable
	The Company’s 4% convertible notes matured on June 1, 2013, and the Company repaid in full at maturity the outstanding principal amount of $115.8 million, together with accrued interest thereon. As of December 31, 2012, the principal amount of the convertible notes outstanding was $115.8 million.
	During 2012, the Company retired $13.6 million in principal amount of its then outstanding 4% convertible notes at a price above par and wrote-off approximately $62,000 of deferred debt issuance costs.  As of December 31, 2012, the balance of unamortized deferred debt issuance costs was approximately $0.2 million.
	Accrued interest (included in accrued expenses) on the Company’s 4% convertible notes amounted to $0.4 million as of December 31, 2012.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	(8)  Stockholders’ Equity
	On December 21, 2010, the Company announced that its Board of Directors had authorized a share repurchase program, under which the Company is authorized to repurchase up to $200.0 million of the Company’s outstanding common stock. The Company has suspended repurchases under the share repurchase program. No shares were purchased during the first nine months of 2013. During the second quarter of 2012, the Company repurchased and retired 788,300 shares at a cost of $5.3 million under this program.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	(9)  Supplemental Cash Flow Information
	The Company considers all highly liquid investment securities with maturities when purchased of three months or less to be cash equivalents. During the nine months ended September 30, 2013 and 2012, there were interest payments of $2.3 million and $4.8 million, respectively, related to the Company’s notes payable. Income tax payments of $158,000 and $33,000 were made during the nine months ended September 30, 2013 and 2012, respectively.

Earnings_Per_Common_Share

Earnings Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	(10)  Earnings Per Common Share
	Basic earnings per common share is computed by dividing the income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Restricted stock units (nonvested shares) are not considered to be outstanding shares until the vesting criteria (service and/or performance) have been satisfied.
	For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and the number of shares issuable upon conversion of the Company’s convertible notes payable for the period that they were outstanding.  As of September 30, 2013, shares issuable under the employee stock purchase plan (ESPP) no longer have a dilutive effect due to the plan termination. Earnings per common share information as follows (in thousands, except per share amounts):
		Three months ended					Nine months ended
		September 30,					September 30,
		2013		2012			2013			2012
	Income Per Common Share – Basic:
	Net income	$	5,562	$	4,175		$	12,671		$	2,375
	Weighted-average common shares outstanding		43,921		46,387			43,782			47,614
	Basic income per share	$	0.13	$	0.09		$	0.29		$	0.05
	Income Per Common Share – Diluted:
	Net income	$	5,562	$	4,175		$	12,671		$	2,375
	Add-back of interest expense on outstanding		-		753			1,142			-
	convertible notes payable, net of tax
	Adjusted net income	$	5,562	$	4,928		$	13,813		$	2,375
	Weighted-average common shares outstanding		43,921		46,387			43,782			47,614
	Weighted-average incremental shares related to		216		45			172			57
	assumed exercise of stock options, vesting
	of nonvested shares, and ESPP
	Weighted-average incremental shares assuming		-		12,131	-1		9,514	-1		-
	conversion of outstanding notes payable
	Weighted-average common shares outstanding		44,137		58,563			53,468			47,671
	and common share equivalents
	Diluted income per share	$	0.13	$	$0.08		$	0.26		$	0.05
	(1)   Dilutive convertible notes payable, which were retired on June 1, 2013, were included in the denominator of diluted EPS for the period that they were outstanding.

Restructurings

Restructurings	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	(11)  Restructurings
	In December 2012, the Company announced a plan to reduce its workforce by approximately 15-20 employees.  In March 2013, in an effort to continue to cut ongoing operating expenses, the Company committed to a plan to reduce its workforce from 19 employees to 12 employees. The Company continued to reduce its workforce during the second quarter of 2013 from 12 to 5 employees.  The Company had 4 employees at the end of the third quarter of 2013.
	During the first quarter of 2013, the Company incurred restructuring charges of $2.5 million, of which $1.6 million resulted in cash expenditures paid during the first quarter.
	During the second quarter of 2013, the Company incurred restructuring charges of $596,000, of which $501,000 resulted in cash expenditures paid during the second quarter and $95,000 remained to be paid for one-time employee termination benefits and associated costs. The Company also reversed previously recognized expense of $132,000 due to changes in estimates of employee separation costs.
	During the third quarter of 2013, the Company incurred restructuring charges of $794,000, primarily related to the sublease of 30,000 square feet of space in its headquarters, representing the present value of future lease obligations in excess of future sublease income.  The Company has classified $503,000 of the charge as current and $291,000 as non-current.
	The Company has also incurred costs from restructuring activities undertaken during 2011 as part of the transition from a fully integrated biopharmaceutical company with research, manufacturing, and marketing operations to a biotechnology company focused primarily on research and development. During the second half of 2011, the Company incurred additional restructuring costs as part of a plan to more closely align its resources and capital with on-going research and development activities.
	Restructuring costs are charged to earnings and accrued as a liability at the time they are considered probable and reasonably estimable. Restructuring costs include employee separation benefits and lease termination costs for facilities that have been vacated and are included in accrued expenses on the accompanying Condensed Consolidated Balance Sheets.
	The following table summarizes the changes in the Company’s accrued restructuring liabilities during the first three quarters of 2013 (in thousands) based on the quarter in which the related restructuring measures were initiated:
		3Q-13	2Q-13	1Q-13	4Q-11	3Q-11	2Q-11	Total
	Balance at December 31, 2012	-	-	-	6	769	1	776
	1Q2013 Payment made	-	-	-1,583	-4	-254	-1	-1,842
	1Q2013 Adjustments	-	-	-	-	-23	-	-23
	1Q2013 Restructuring Accruals	-	-	2,505	-	29	-	2,534
	Balance at March 31, 2013	-	-	922	2	521	-	1,445
	2Q2013 Payment made	-	-501	-757	-2	-460	-	-1,720
	2Q2013 Adjustments	-	-	-103	-	-29	-	-132
	2Q2013 Restructuring Accruals	-	596	-	-	-	-	596
	Balance at June 30, 2013	-	95	62	-	32	-	189
	3Q2013 Payment made	-	-82	-32	-	-15	-	-129
	3Q2013 Adjustments	-	-	-	-	-	-	-
	3Q2013 Restructuring Accruals	794	-	-	-	-	-	794
	Balance at September 30, 2013	794	13	30	-	17	-	854

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	(12) Stock-Based Compensation
	Stock Options and Restricted Stock Units (RSUs or Nonvested Shares)
	During the quarter ended September 30, 2013, the Company recognized stock-based compensation expense of $0.3 million. Shares were withheld to pay $0.1 million of taxes on behalf of employees whose restricted stock units (RSUs) vested during the quarter, resulting in a credit to additional paid-in capital of $0.2 million. During the quarter ended September 30, 2012, the Company recognized stock-based compensation expense of $0.6 million.  Shares were withheld to pay $0.1 million of taxes on behalf of employees during the quarter ended September 30, 2012, resulting in a net incremental credit of additional paid in capital of $0.5 million.
	During the nine months ended September 30, 2013, the Company reversed stock-based compensation expense of $50,000. Shares were withheld to pay $0.3 million of taxes on behalf of employees, resulting in a net incremental debit to additional paid-in capital of $0.3 million. During the nine months ended September 30, 2012, the Company recognized stock-based compensation expense of $1.5 million. Shares were withheld to pay $0.1 million of taxes on behalf of employees, resulting in a net incremental credit to additional paid-in capital of $1.4 million.
	As of September 30, 2013, there was $0.2 million of total unrecognized compensation cost related to unvested stock options that the Company expects to recognize over a weighted-average period of 11 months and $0.8 million of total unrecognized compensation cost related to nonvested shares to be recognized over a weighted-average period of 14 months.
	During the nine months ended September 30, 2013, the Company granted 156,000 stock options, all of which were granted during the first quarter. The aggregate fair value of stock options granted during the nine months ended September 30, 2013 was $0.2 million. There were no nonvested shares granted during the nine months ended September 30, 2013. The Company uses historical data to estimate forfeiture rates.
	On April 23, 2013, the Company’s Board of Directors declared a special cash dividend of $1.60 per share of common stock. This special cash dividend was paid on June 4, 2013 to stockholders of record as of May 7, 2013. In connection with this special cash dividend, the Compensation Committee of the Company’s Board of Directors approved equitable adjustments to the Company’s outstanding stock options and restricted stock units. The compensation cost recognized during 2013 relating to this modification was $4,000.
	Activity related to stock options and nonvested shares during the nine months ended September 30, 2013 and related balances outstanding as of that date are reflected below (in thousands):
		Stock	Nonvested
		Options	Shares
	Outstanding at January 1, 2013	2,292	868
	Granted	156	-
	Exercised and vested	-	-507
	Expired and forfeited	-159	-378
	Adjustment pursuant to special dividend	-	438
	Outstanding at September 30, 2013	2,289	421
	Options vested and expected to vest at September 30, 2013	2,250
	Options exercisable at September 30, 2013	2,034

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	(13)  Income Taxes
	During the three months ended September 30, 2013, the Company reversed $186,000 of income tax expense for U.S. federal income tax provision related to alternative minimum taxes, and reversed $55,000 of income tax expense related to foreign jurisdictions due to a provision for bad debts related to Hisun. During the three months ended September 30, 2012, the Company recorded no income tax expense because the estimated annual effective tax rate was zero.
	During the nine months ended September 30, 2013 and 2012, the Company recorded an income tax benefit of $28,000 and income tax expense of $33,000, respectively.  The Company’s expected tax rate for 2013 is zero.
	As of September 30, 2013, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized within the next twelve months.

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessor Disclosure [Text Block]	'
	(14)  Commitments and Contingent Liabilities
	On September 27, 2013, the Company entered into a separation agreement with Andrew Rackear, the Company’s Vice President and General Counsel, that provides for severance payments and payments following a termination of employment, which is scheduled to occur during the fourth quarter.  The separation agreement provides that, upon termination of Mr. Rackear’s employment with the Company, Mr. Rackear will be entitled to receive a severance payment in cash equal to $835,000 plus other benefits.  The Company expects to record a charge related to this agreement during the fourth quarter of 2013.
	The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.
	The Company had a non-cancelable lease obligation for certain office and production facilities that had been vacated and sublet. During 2013, the Company terminated the lease of the Bridgewater, New Jersey facility.
	On September 26, 2013, the Company entered into an Agreement of Sublease with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company will sublease to Axcellerate a portion of the Company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas (the “Sublease”). The Company’s premises located at 20 Kingsbridge Road, Piscataway, New Jersey are currently leased by the Company pursuant to an agreement of lease dated as of April 1, 1995, as amended by that certain First Amendment to Lease dated as of November 13, 2001 (the “Prime Lease”), with BDG Kingsbridge L.L.C., predecessor-in-interest to Kingsbridge 2005, LLC (“Prime Landlord”). The Sublease is subject to the Company’s receipt of the Prime Landlord’s consent to the Sublease. The term of the Sublease will commence on the date that the Company has received the Prime Landlord’s consent to the Sublease and will expire on July 30, 2021, which is one day prior to the expiration of the Prime Lease. The rights of Axcellerate under the Sublease will be subject to the terms of the Prime Lease. The monthly fixed rent payable by Axcellerate under the Sublease will be as follows: (i) in year one, $10,417, (ii) in year two, $15,625, (iii) in year three, $20,833, (iv) in year four, $26,042 and (v) in each of years five through eight, $35,000. The Sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.
	Below is a table showing the projected sublease rent payments as well as the Company’s projected lease payments related to the subleased premises (in thousands of dollars):
		2013	2014	2015	2016	2017	Thereafter	Total
	Projected sublease rent payments	22	135	198	267	362	1,505	2,489
	Lease payments related to subleased premises	65	373	374	374	394	1,472	3,052

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	(15)  Subsequent Event
	On October 21, 2013, the Company terminated its License and Collaboration Agreement with Santaris whereby Enzon will return to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin. The termination includes the return of certain product inventory and a net cash payment to Santaris of approximately $450,000 as well as certain transition expenses to be borne by Enzon of up to $50,000. The Company and Santaris each agreed to release any and all claims it may have against the other in connection with the License and Collaboration Agreement. The Company accrued a charge of $500,000 during the three months ended September 30, 2013 for the termination of the Santaris Agreement, included within research and development expenses.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Interim Financial Statements [Policy Text Block]	'
	Interim Financial Statements
	The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Available-for-sale Securities [Table Text Block]	'
	The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2012 were as follows (in thousands):
		Amortized		Gross		Gross		Fair
		Cost		Unrealized		Unrealized		Value*
				Holding Gains		Holding Losses
	Corporate bonds	$	86,769	$	82	$	-11	$	86,840
	Commercial paper		30,482		8		-		30,490
	U.S. government-sponsored agency		2,057		4		-		2,061
		$	119,308	$	94	$	-11	$	119,391
	*     Included in current marketable securities at December 31, 2012.

Earnings_Per_Common_Share_Tabl

Earnings Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	Earnings per common share information as follows (in thousands, except per share amounts):
		Three months ended					Nine months ended
		September 30,					September 30,
		2013		2012			2013			2012
	Income Per Common Share – Basic:
	Net income	$	5,562	$	4,175		$	12,671		$	2,375
	Weighted-average common shares outstanding		43,921		46,387			43,782			47,614
	Basic income per share	$	0.13	$	0.09		$	0.29		$	0.05
	Income Per Common Share – Diluted:
	Net income	$	5,562	$	4,175		$	12,671		$	2,375
	Add-back of interest expense on outstanding		-		753			1,142			-
	convertible notes payable, net of tax
	Adjusted net income	$	5,562	$	4,928		$	13,813		$	2,375
	Weighted-average common shares outstanding		43,921		46,387			43,782			47,614
	Weighted-average incremental shares related to		216		45			172			57
	assumed exercise of stock options, vesting
	of nonvested shares, and ESPP
	Weighted-average incremental shares assuming		-		12,131	-1		9,514	-1		-
	conversion of outstanding notes payable
	Weighted-average common shares outstanding		44,137		58,563			53,468			47,671
	and common share equivalents
	Diluted income per share	$	0.13	$	$0.08		$	0.26		$	0.05
	(1)   Dilutive convertible notes payable, which were retired on June 1, 2013, were included in the denominator of diluted EPS for the period that they were outstanding.

Restructurings_Tables

Restructurings (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs [Table Text Block]	'
	The following table summarizes the changes in the Company’s accrued restructuring liabilities during the first three quarters of 2013 (in thousands) based on the quarter in which the related restructuring measures were initiated:
		3Q-13	2Q-13	1Q-13	4Q-11	3Q-11	2Q-11	Total
	Balance at December 31, 2012	-	-	-	6	769	1	776
	1Q2013 Payment made	-	-	-1,583	-4	-254	-1	-1,842
	1Q2013 Adjustments	-	-	-	-	-23	-	-23
	1Q2013 Restructuring Accruals	-	-	2,505	-	29	-	2,534
	Balance at March 31, 2013	-	-	922	2	521	-	1,445
	2Q2013 Payment made	-	-501	-757	-2	-460	-	-1,720
	2Q2013 Adjustments	-	-	-103	-	-29	-	-132
	2Q2013 Restructuring Accruals	-	596	-	-	-	-	596
	Balance at June 30, 2013	-	95	62	-	32	-	189
	3Q2013 Payment made	-	-82	-32	-	-15	-	-129
	3Q2013 Adjustments	-	-	-	-	-	-	-
	3Q2013 Restructuring Accruals	794	-	-	-	-	-	794
	Balance at September 30, 2013	794	13	30	-	17	-	854

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Activity related to stock options and nonvested shares during the nine months ended September 30, 2013 and related balances outstanding as of that date are reflected below (in thousands):
		Stock	Nonvested
		Options	Shares
	Outstanding at January 1, 2013	2,292	868
	Granted	156	-
	Exercised and vested	-	-507
	Expired and forfeited	-159	-378
	Adjustment pursuant to special dividend	-	438
	Outstanding at September 30, 2013	2,289	421
	Options vested and expected to vest at September 30, 2013	2,250
	Options exercisable at September 30, 2013	2,034

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
	(14)  Commitments and Contingent Liabilities
	On September 27, 2013, the Company entered into a separation agreement with Andrew Rackear, the Company’s Vice President and General Counsel, that provides for severance payments and payments following a termination of employment, which is scheduled to occur during the fourth quarter.  The separation agreement provides that, upon termination of Mr. Rackear’s employment with the Company, Mr. Rackear will be entitled to receive a severance payment in cash equal to $835,000 plus other benefits.  The Company expects to record a charge related to this agreement during the fourth quarter of 2013.
	The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.
	The Company had a non-cancelable lease obligation for certain office and production facilities that had been vacated and sublet. During 2013, the Company terminated the lease of the Bridgewater, New Jersey facility.
	On September 26, 2013, the Company entered into an Agreement of Sublease with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company will sublease to Axcellerate a portion of the Company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas (the “Sublease”). The Company’s premises located at 20 Kingsbridge Road, Piscataway, New Jersey are currently leased by the Company pursuant to an agreement of lease dated as of April 1, 1995, as amended by that certain First Amendment to Lease dated as of November 13, 2001 (the “Prime Lease”), with BDG Kingsbridge L.L.C., predecessor-in-interest to Kingsbridge 2005, LLC (“Prime Landlord”). The Sublease is subject to the Company’s receipt of the Prime Landlord’s consent to the Sublease. The term of the Sublease will commence on the date that the Company has received the Prime Landlord’s consent to the Sublease and will expire on July 30, 2021, which is one day prior to the expiration of the Prime Lease. The rights of Axcellerate under the Sublease will be subject to the terms of the Prime Lease. The monthly fixed rent payable by Axcellerate under the Sublease will be as follows: (i) in year one, $10,417, (ii) in year two, $15,625, (iii) in year three, $20,833, (iv) in year four, $26,042 and (v) in each of years five through eight, $35,000. The Sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.
	Below is a table showing the projected sublease rent payments as well as the Company’s projected lease payments related to the subleased premises (in thousands of dollars):
		2013	2014	2015	2016	2017	Thereafter	Total
	Projected sublease rent payments	22	135	198	267	362	1,505	2,489
	Lease payments related to subleased premises	65	373	374	374	394	1,472	3,052

Description_of_Business_Detail

Description of Business (Details Textual) (USD $)	1 Months Ended
	Apr. 30, 2013
Description of Business [Line Items]	'
Sale Of Assets, Consideration Received On Transaction	$700,000
Sale Of Assets, Escrow Deposit	$100,000

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Schedule of Trading Securities and Other Trading Assets [Line Items]	'
Amortized Cost	$119,308
Gross, Unrealized Holding Gains	94
Gross, Unrealized Holding Losses	-11
Fair Value	119,391	[1]
Corporate Debt Securities [Member]	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'
Amortized Cost	86,769
Gross, Unrealized Holding Gains	82
Gross, Unrealized Holding Losses	-11
Fair Value	86,840	[1]
Commercial Paper [Member]	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'
Amortized Cost	30,482
Gross, Unrealized Holding Gains	8
Gross, Unrealized Holding Losses	0
Fair Value	30,490	[1]
Us Government Agencies Debt Securities [Member]	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'
Amortized Cost	2,057
Gross, Unrealized Holding Gains	4
Gross, Unrealized Holding Losses	0
Fair Value	$2,061	[1]
[1]	Included in current marketable securities at December 31, 2012.

Marketable_Securities_Details_

Marketable Securities (Details Textual) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'
Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds	$1	$0.30	$1	'
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	'	'	'	$38.10

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Short-term Debt [Line Items]	'	'	'
Notes Payable Reduction	$115,849,000	$0	$13,600,000
Write off of Deferred Debt Issuance Cost	'	'	62,000
Unamortized Debt Issuance Expense	'	'	200,000
Debt Instrument, Interest Rate, Stated Percentage	4.00%	'	4.00%
Notes payable	'	'	115,800,000
Four Percent Convertible Debt [Member]	'	'	'
Short-term Debt [Line Items]	'	'	'
Interest Payable, Current	'	'	$400,000
Debt Instrument, Interest Rate, Stated Percentage	'	'	4.00%

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	1 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2010	Jun. 30, 2012
Class of Stock [Line Items]	'	'
Stock Repurchase Program, Authorized Amount	$200	'
Stock Repurchased and Retired During Period, Shares	'	788,300
Stock Repurchased and Retired During Period, Value	'	$5.30

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Noncash or Part Noncash Acquisitions [Line Items]	'	'
Interest Paid	$2,300,000	$4,800,000
Income Taxes Paid	$158,000	$33,000

Earnings_Per_Common_Share_Deta

Earnings Per Common Share (Details) (USD $)	3 Months Ended			9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Income Per Common Share - Basic:	'	'		'		'
Net income	$5,562	$4,175		$12,671		$2,375
Weighted-average common shares outstanding	43,921	46,387		43,782		47,614
Basic income per share (in dollars per share)	$0.13	$0.09		$0.29		$0.05
Income Per Common Share - Diluted:	'	'		'		'
Net income	5,562	4,175		12,671		2,375
Add-back of interest expense on outstanding convertible notes payable, net of tax	0	753		1,142		0
Adjusted net income	$5,562	$4,928		$13,813		$2,375
Weighted-average common shares outstanding	43,921	46,387		43,782		47,614
Weighted-average incremental shares related to assumed exercise of stock options, vesting of nonvested shares, and ESPP	216	45		172		57
Weighted-average incremental shares assuming conversion of outstanding notes payable	0	12,131	[1]	9,514	[1]	0
Weighted-average common shares outstanding and common share equivalents	44,137	58,563		53,468		47,671
Diluted income per share (in dollars per share)	$0.13	$0.08		$0.26		$0.05
[1]	Dilutive convertible notes payable, which were retired on June 1, 2013, were included in the denominator of diluted EPS for the period that they were outstanding.

Restructurings_Details

Restructurings (Details) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	$189,000	$1,445,000	$776,000
Payment made	-129,000	-1,720,000	-1,842,000
adjustments	0	-132,000	-23,000
Restructuring Accruals	794,000	596,000	2,534,000
Ending Balance	854,000	189,000	1,445,000
Third-Quarter 2013 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	0	0	0
Payment made	0	0	0
adjustments	0	0	0
Restructuring Accruals	794,000	0	0
Ending Balance	794,000	0	0
Second-Quarter 2013 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	95,000	0	0
Payment made	-82,000	-501,000	0
adjustments	0	0	0
Restructuring Accruals	0	596,000	0
Ending Balance	13,000	95,000	0
First -Quarter 2013 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	62,000	922,000	0
Payment made	-32,000	-757,000	-1,583,000
adjustments	0	-103,000	0
Restructuring Accruals	0	0	2,505,000
Ending Balance	30,000	62,000	922,000
Fourth-Quarter 2011 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	0	2,000	6,000
Payment made	0	-2,000	-4,000
adjustments	0	0	0
Restructuring Accruals	0	0	0
Ending Balance	0	0	2,000
Third-Quarter 2011 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	32,000	521,000	769,000
Payment made	-15,000	-460,000	-254,000
adjustments	0	-29,000	-23,000
Restructuring Accruals	0	0	29,000
Ending Balance	17,000	32,000	521,000
Second-Quarter 2011 [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Beginning Balance	0	0	1,000
Payment made	0	0	-1,000
adjustments	0	0	0
Restructuring Accruals	0	0	0
Ending Balance	$0	$0	$0

Restructurings_Details_Textual

Restructurings (Details Textual) (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Employees

sqft

First Quarter Two Thousand Thirteen [Member]

First Quarter Two Thousand Thirteen [Member]

First Quarter Two Thousand Thirteen [Member]

First Quarter Two Thousand Thirteen [Member]

Second Quarter Two Thousand Thirteen [Member]

Second Quarter Two Thousand Thirteen [Member]

Second Quarter Two Thousand Thirteen [Member]

Second Quarter Two Thousand Thirteen [Member]

Third quater two thousand thirteen [Member]

Third quater two thousand thirteen [Member]

Third quater two thousand thirteen [Member]

Third quater two thousand thirteen [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Employee Severance [Member]

sqft

Employees

Employees

Employees

Employees

Employees

Employees

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Severance Costs

'

'

'

'

$132,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

794,000

'

2,500,000

-113,000

'

3,764,000

-220,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Related Cost, Expected Number of Positions Eliminated

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

19

20

5

12

15

'

Payments for Restructuring

129,000

1,720,000

1,842,000

'

'

'

'

'

32,000

757,000

1,583,000

'

82,000

501,000

0

'

0

0

0

'

'

'

'

'

'

'

835,000

Restructuring Accruals

794,000

596,000

2,534,000

'

'

'

'

'

0

0

2,505,000

'

0

596,000

0

'

794,000

0

0

'

'

'

'

'

'

'

'

Restructuring Reserve

854,000

189,000

1,445,000

'

189,000

854,000

'

776,000

30,000

62,000

922,000

0

13,000

95,000

0

0

794,000

0

0

0

'

'

'

'

'

'

'

Area of Land

30,000

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve, Current

503,000

'

'

'

'

503,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve, Noncurrent

$291,000

'

'

'

'

$291,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Detail

Stock-Based Compensation (Details)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'
Outstanding at January 1, 2013, Stock Options	2,292
Granted , Stock Options	156
Exercised and vested, Stock Options	0
Expired and forfeited, Stock Options	-159
Adjustment pursuant to special dividend, Stock Options	0
Outstanding at September 30, 2013, Stock Options	2,289
Options vested and expected to vest at September 30, 2013, Stock Options	2,250
Options exercisable at September 30, 2013, Stock Options	2,034
Outstanding at January 1, 2013, Nonvested Shares	868
Granted, Nonvested Shares	0
Exercised and vested, Nonvested Shares	-507
Expired and Forfeited, Nonvested Shares	-378
Adjustment pursuant to special dividend, Nonvested Shares	438
Outstanding at September 30, 2013, Nonvested Shares	421

StockBased_Compensation_Detail1

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		9 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Reversed Share Based Compensation	'	'	$50,000	'
Withholding taxes stock-based compensation	100,000	100,000	300,000	100,000
Additional Paid In Capital Net Incremental Credit	200,000	500,000	300,000	1,400,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	'	'	200,000	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	200,000	'	200,000	'
Unallocated Share Based Compensation Expense	800,000	'	800,000	'
Common Stock, Dividends, Per Share, Cash Paid	$0	$0	$1.60	$0
Allocated Share-based Compensation Expense	'	'	4,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	'	'	156	'
Share-based Compensation, Total	$300,000	$600,000	($54,000)	$1,550,000
Employee Stock Option [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'11 months	'
Nonvested Shares [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'14 months	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Line Items]	'	'	'	'
Income tax (benefit) expense	($241,000)	$0	($28,000)	$33,000
Current Federal Tax Expense (Benefit)	186,000	'	'	'
Current Foreign Tax Expense (Benefit)	$55,000	'	'	'

Commitments_and_Contingent_Lia2

Commitments and Contingent Liabilities (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Disclosure Of Commitments And Contingent [Line Items]	'
Projected sublease, 2013	$22
Projected sublease, 2014	135
Projected sublease, 2015	198
Projected sublease, 2016	267
Projected sublease, 2017	362
Projected sublease, Thereafter	1,505
Projected sublease, Total	2,489
Lease payments, 2013	65
Lease payments, 2014	373
Lease payments, 2015	374
Lease payments, 2016	374
Lease payments, 2017	394
Lease payments, Thereafter	1,472
Lease payments, Total	$3,052

Commitments_and_Contingent_Lia3

Commitments and Contingent Liabilities (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
	sqft
Disclosure Of Commitments And Contingent [Line Items]	'	'	'
Area of Land	30,000	'	'
Monthly Fixed Rent Receivable On Sublease, Year One	$10,417	'	'
Monthly Fixed Rent Receivable On Sublease, Year Two	15,625	'	'
Monthly Fixed Rent Receivable On Sublease, Year Three	20,833	'	'
Monthly Fixed Rent Receivable On Sublease, Year Four	26,042	'	'
Payments for Restructuring	129,000	1,720,000	1,842,000
Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight	35,000	'	'
Employee Severance [Member]	'	'	'
Disclosure Of Commitments And Contingent [Line Items]	'	'	'
Payments for Restructuring	$835,000	'	'

Subsequent_Event_Details_Textu

Subsequent Event (Details Textuals) (USD $)	3 Months Ended	1 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
		Subsequent Event [Member]
Subsequent Event [Line Items]	'	'
Approximate Payments For Termination Of License And Collaboration Agreement	'	$450,000
Termination Of License And Collaboration Agreement Research And Development Expenses Charged	500,000	'
Termination Of License And Collaboration Agreement Transition Expenses Borne By Entity	'	$50,000